Skip to Content
Søg Menu
Velkommen til lungecancer

Få de seneste artikler og MEDtalks om lungecancer

Seneste nyt om lungecancer

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

  • / Jan Andreasen
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
WCLC25Lungecancer Play the Video
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
NSCLCLungecancer Play the Video
Edyta Maria Urbanska

Behandling af patienter med lungecancer og positiv for NTRK-fusioner

/ Edyta Maria Urbanska
Lungecancer Play the Video

Artikler

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
WCLC25NSCLCLungecancer

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
NSCLCLungecancer

Jens Benns møde med Heine var skelsættende for valget af lungeonkologien

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungecancer

Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC

/ Antonio Passaro / Jan Andreasen
Lungecancer

Thoraxpatologien er en aktiv faktor i behandlingen af lungecancer

/ Eric Santoni Rugiu / Amanda Feldballe Bernholm
Lungecancer

Eric Santoni-Rugiu: Vejen fra leverpatologi til nyudnævnt professor i thorakal patologi 

/ Eric Santoni Rugiu / Jan Andreasen
Lungecancer

WCLC I Kongresside

6.-9. september 2025

Se mere

MEDtalks

Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungecancer Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungecancer Play the Video
Edyta Maria Urbanska

Amivantamab + lazartinib i 1.-linje øger overlevelsen ved avanceret EGFR muteret NSCLC vs osimertinib

/ Edyta Maria Urbanska
Lungecancer Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungecancer Play the Video
Nicolas Girard

Prophylactic Treatment Lowers Skin Toxicity in NSCLC Patients on Amivantamab + Lazertinib

/ Nicolas Girard
Lungecancer Play the Video
Bjørn Henning Grønberg

Norge har indført 1. valg af lorlatinib til patienter med avanceret ALK-positiv NSCLC på baggrund af flotte PFS data

/ Bjørn Henning Grønberg
Lungecancer Play the Video
Hent flere

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungecancer

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungecancer
Jens Benn Sørensen

Highlights fra ESMO 2024 om lungecancer

/ Jens Benn Sørensen
ESMO24Lungecancer Play the Video

Outstanding Results for the Treatment of Lung Cancer

/ Tony Mok
Lungecancer Play the Video
Bjørn H. Grønberg

Høydepunkter fra ESMO 2024 om lungekreft

/ Bjørn Henning Grønberg
ESMO24Lungecancer Play the Video
Edyta Maria Urbanska

New Tendencies in Development of ALK-TKIs for Treatment of ALK-Rearranged NSCLC

/ Edyta Maria Urbanska
Lungecancer Play the Video
Oluf Dimitri Røe

ASCO24: Very Exciting Steps for Early Diagnosis and Lung Cancer

/ Oluf Dimitri Røe
ASCO24Lungecancer Play the Video
Edyta Maria Urbanska

Younger Patients with Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors Seem to be Prone to Return to Work

/ Edyta Maria Urbanska
Lungecancer Play the Video
Hent flere
Back to top